These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16323566)

  • 1. [Insulin resistance: the adipose tissue in the focus].
    Urich E
    Orv Hetil; 2005 Oct; 146(43):2199-207. PubMed ID: 16323566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization.
    Saraf N; Sharma PK; Mondal SC; Garg VK; Singh AK
    J Pharm Pharmacol; 2012 Feb; 64(2):161-71. PubMed ID: 22221092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones.
    Yki-Järvinen H
    N Engl J Med; 2004 Sep; 351(11):1106-18. PubMed ID: 15356308
    [No Abstract]   [Full Text] [Related]  

  • 4. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones.
    Zirlik A; Leugers A; Lohrmann J; Ernst S; Sobel BE; Bode C; Nordt TK
    Thromb Haemost; 2004 Apr; 91(4):674-82. PubMed ID: 15045127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
    Liu LF; Purushotham A; Wendel AA; Belury MA
    Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of PPARgamma ligands on the adipose tissue in insulin resistance.
    Hammarstedt A; Andersson CX; Rotter Sopasakis V; Smith U
    Prostaglandins Leukot Essent Fatty Acids; 2005 Jul; 73(1):65-75. PubMed ID: 15936183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
    Hoo RL; Chow WS; Yau MH; Xu A; Tso AW; Tse HF; Fong CH; Tam S; Chan L; Lam KS
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2777-82. PubMed ID: 17932317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotyping of adipose, liver, and skeletal muscle insulin resistance and response to pioglitazone in spontaneously obese rhesus monkeys.
    Shang J; Previs SF; Conarello S; Chng K; Zhu Y; Souza SC; Staup M; Chen Y; Xie D; Zycband E; Schlessinger K; Johnson VP; Arreaza G; Liu F; Levitan D; Wang L; van Heek M; Erion M; Wang Y; Kelley DE
    Am J Physiol Endocrinol Metab; 2017 Apr; 312(4):E235-E243. PubMed ID: 28143858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells.
    Cipolletta D; Feuerer M; Li A; Kamei N; Lee J; Shoelson SE; Benoist C; Mathis D
    Nature; 2012 Jun; 486(7404):549-53. PubMed ID: 22722857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-37 protects against obesity-induced inflammation and insulin resistance.
    Ballak DB; van Diepen JA; Moschen AR; Jansen HJ; Hijmans A; Groenhof GJ; Leenders F; Bufler P; Boekschoten MV; Müller M; Kersten S; Li S; Kim S; Eini H; Lewis EC; Joosten LA; Tilg H; Netea MG; Tack CJ; Dinarello CA; Stienstra R
    Nat Commun; 2014 Sep; 5():4711. PubMed ID: 25182023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased adipose tissue expression of Grb14 in several models of insulin resistance.
    Cariou B; Capitaine N; Le Marcis V; Vega N; Béréziat V; Kergoat M; Laville M; Girard J; Vidal H; Burnol AF
    FASEB J; 2004 Jun; 18(9):965-7. PubMed ID: 15059968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit.
    Papaetis GS; Orphanidou D; Panagiotou TN
    Curr Drug Targets; 2011 Sep; 12(10):1498-512. PubMed ID: 21675944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
    Hiuge-Shimizu A; Maeda N; Hirata A; Nakatsuji H; Nakamura K; Okuno A; Kihara S; Funahashi T; Shimomura I
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):792-9. PubMed ID: 21233451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome.
    Matsuura N; Asano C; Nagasawa K; Ito S; Sano Y; Minagawa Y; Yamada Y; Hattori T; Watanabe S; Murohara T; Nagata K
    Int J Cardiol; 2015 Jan; 179():360-9. PubMed ID: 25464487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic inflammation: connecting obesity and insulin resistance.
    Dali-Youcef N; Mecili M; Ricci R; Andrès E
    Ann Med; 2013 May; 45(3):242-53. PubMed ID: 22834949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redox implications in adipose tissue (dys)function--A new look at old acquaintances.
    Jankovic A; Korac A; Buzadzic B; Otasevic V; Stancic A; Daiber A; Korac B
    Redox Biol; 2015 Dec; 6():19-32. PubMed ID: 26177468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adipose tissue dysfunction in obesity.
    Blüher M
    Exp Clin Endocrinol Diabetes; 2009 Jun; 117(6):241-50. PubMed ID: 19358089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased STAMP2 expression in association with visceral adipose tissue dysfunction.
    Moreno-Navarrete JM; Ortega F; Serrano M; Pérez-Pérez R; Sabater M; Ricart W; Tinahones F; Peral B; Fernández-Real JM
    J Clin Endocrinol Metab; 2011 Nov; 96(11):E1816-25. PubMed ID: 21849520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.